We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (3352)12/23/2002 4:26:13 PM
From: scaram(o)ucheRespond to of 4974
one of best T.V. commercials ever.....

Jack in the Box......

son asking Jack, "what's the difference between boys and girls"?

shows a bunch of pristine young girls, dancing and hugging plush unicorns.

shows a boy, sitting in a sand pit with bucket over head, banging on the bucket with shovel.

then comments on our attention span at the end.

To: scaram(o)uche who wrote (3352)12/23/2002 4:31:06 PM
From: Miljenko ZuanicRespond to of 4974
Anyone who got cash bonus and options award while comp MC decline <20% in '02 is on list. No exception. No veto!

To: scaram(o)uche who wrote (3352)12/24/2002 2:29:11 PM
From: JOEBT1Read Replies (1) | Respond to of 4974
Richard--My candidate for worst CEO is David Robinson (sp?) of LGND. Happy holidays!

To: scaram(o)uche who wrote (3352)1/21/2003 4:32:35 PM
From: rkrwRead Replies (1) | Respond to of 4974
Hate to nominate him since I did so well with his former company, Geltex, but...
Mark Skaletsky, Essential Therapeutics (ex-Microcide).

They're in the midst of a complete disaster for s/h and on the verge of losing the company to convertible pfd shareholders. etrx stock is trading for all of 26 cents.
Most disastrous financing I've seen in a long time. One would have thought Skaletsky would have known better than to raise money with toxic securities.

To: scaram(o)uche who wrote (3352)2/24/2003 2:29:33 PM
From: scaram(o)ucheRespond to of 4974
Message 18367350

Guilford Pharmaceuticals Announces Updated Fourth Quarter and Year End Financial Results
Monday February 24, 1:33 pm ET

BALTIMORE, Feb. 24 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc. (Nasdaq: GLFD - News) announced today it is re-issuing its previously announced financial results for the fourth quarter and year ended December 31, 2002. The net loss for 2002 has been reduced from $60.0 million to $59.3 million and the net loss per share has been reduced from $2.01 per share to $1.99 per share. For the fourth quarter, the net loss has been reduced from $15.1 million to $14.3 million, or from $0.50 per share to $0.48 per share. The reduction in net loss is due to the elimination of $730,000 in accrued cash incentives. The Company's Board of Directors implemented the cash savings principally through the elimination of cash incentives for executives.
Guilford Pharmaceuticals Inc. is a fully integrated pharmaceutical company that discovers, develops and markets novel pharmaceutical products targeting the hospital and neurological markets.

Contact: Guilford Pharmaceuticals Inc.
Stacey Jurchison 410.631.5022

Source: Guilford Pharmaceuticals, Inc.